Multi-Institutional Retrospective Analysis of the Outcomes of Proton Beam Therapy for Patients With 1 to 3 Pulmonary Oligometastases From Various Primary Cancers

Aibe, Norihiro; Ogino, Hiroyuki; Teramukai, Satoshi; Yamazaki, Hideya; Iwata, Hiromitsu; Matsuo, Yoshiro; Okimoto, Tomoaki; Murakami, Masao; Suzuki, Motohisa; Arimura, Takeshi; Ogino, Takashi; Murayama, Shigeyuki; Harada, Hideyuki; Nakamura, Masaki; Akimoto, Tetsuo; Sakurai, Hideyuki

doi:10.1016/j.adro.2021.100690

Cited by 6 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The analysis of the cohort study data set of PT showed durable LC (3-year LC, 83.2%) and OS (3-year OS, 68.1%) with an acceptable risk of grade ≥ 3 toxicity (incidence rate, 0.8%) in metastasis-directed therapy for P-OM. This result corresponded with the results of previous reports on PT for P-OM [ 16–18 ]. The range of the prescribed dose in this cohort series was relatively wide because the prescribed doses depended on the physician’s decisions, based on the size, number and location of a target, surrounding organs at risk (e.g.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Comprehensive analysis of Japanese nationwide cohort data of particle beam therapy for pulmonary, liver and lymph node oligometastases: particle beam therapy versus high-precision X-ray radiotherapy

Aibe

Ogino

Wakatsuki

et al. 2023

Journal of Radiation Research

Self Cite

View full text Add to dashboard Cite

Japanese national oncological experts convened to evaluate the efficacy and safety of particle beam therapy (PT) for pulmonary, liver and lymph node oligometastases (P-OM, L-OM and LN-OM, respectively) and to conduct a statistically comparative analysis of the local control (LC) rate and overall survival (OS) rate of PT versus those of X-ray stereotactic body radiotherapy (X-SBRT) and X-ray intensity-modulated radiotherapy (X-IMRT). They conducted [1] an analysis of the efficacy and safety of metastasis-directed therapy with PT for P-OM, L-OM and LN-OM using a Japanese nationwide multi-institutional cohort study data set; [2] a systematic review of X-ray high-precision radiotherapy (i.e. X-SBRT/X-IMRT) and PT for P-OM, L-OM and LN-OM; and [3] a statistical comparison between LC and OS of the cohort data set in PT and that of the extracted historical data set in X-SBRT/X-IMRT from the preceding systematic review. Safety was evaluated as the incidence of grade ≥ 3 adverse events, while statistical comparisons of LC and OS were conducted by estimating the incidence rate ratios (IRR) for local progression and mortality, respectively. This study demonstrated that PT provided durable LC (3-year LC rate: 72.8–83.2%) with acceptable OS (3-year OS rate: 38.5–68.1%) and risk of severe toxicity incidence of 0.8–3.5% in radical metastasis-directed therapy for P-OM, L-OM and LN-OM. Compared to LC with X-SBRT or X-IMRT, LC with PT was potentially superior for P-OM; superior for L-OM; and equivalent for LN-OM. In particular, this study demonstrated that PT may be a new treatment option for L-OM tumors measuring > 5 cm.

show abstract

Section: Discussionsupporting

confidence: 93%

“…S1 ). In total, five relevant studies on X-SBRT [ 11–15 ] and three relevant studies on PT [ 16–18 ] were identified ( Table 3 ). Different studies had different inclusion criteria, characteristics of patients and primary cancers, and treatment protocols.…”

Section: Resultsmentioning

confidence: 99%

Comprehensive analysis of Japanese nationwide cohort data of particle beam therapy for pulmonary, liver and lymph node oligometastases: particle beam therapy versus high-precision X-ray radiotherapy

Aibe

Ogino

Wakatsuki

et al. 2023

Journal of Radiation Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…The OS rates are comparable to those of lung resection (one-year OS rates: 60%-100%, two-year OS rates: 36%-100%, three-year OS rates: 40.2%-60%) in previous reports [ 6 - 11 ]. A Japanese nationwide multi-institutional retrospective analysis of PBT for one to three lung oligometastases from various cancers reported one-, two-, and three-year LC rates of 92.2%, 86.3%, and 78.4%, respectively [ 16 ]. Local treatment results for lung metastases of esophageal cancer are summarized in Table 5 .…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, we demonstrated the absence of grade 3 or higher AEs. A previous study on PBT for lung oligometastases in various primary cancers reported seven patients with grade 2 AEs (5.9%) and one with grade 3 AEs of radiation dermatitis (0.8%) [ 16 ]. In a study on lung oligometastases in esophageal cancer, three (3.3%) patients had grade 2 AEs, four (4.4%) had grade 3 or higher AEs, and one (1.1%) had grade 5 radiation-induced pneumonitis [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

Proton Beam Therapy for Lung Oligometastatic Recurrence in Patients With Esophageal Cancer

Yamaguchi,

Kato,

Honda

et al. 2023

Cureus

Self Cite

View full text Add to dashboard Cite

Local treatment of oligometastatic esophagogastric cancer has been reported to improve overall survival (OS) compared to systemic therapy alone. This study evaluated the feasibility and safety of proton beam therapy (PBT) for the treatment of lung oligometastatic recurrence in esophageal cancer patients. This single-center historical cohort study enrolled 11 patients who underwent PBT for lung oligometastasis from esophageal cancer between 2010 and 2019. The selection criteria were that the primary esophageal cancer was controlled and no more than three lung metastases without outside lung tumors were present. OS, progression-free survival (PFS), and local control (LC) rates and adverse events (AEs) were assessed. Factors that may be related to OS were also investigated. The median follow-up period was 27.8 months (8.8-141.3 months). The one-, two-, and three-year OS rates were 81.8%, 72.7%, and 51.9%, respectively (median OS time: 43.7 months); PFS rates were 45.5%, 27.3%, and 27.3%, respectively (median PFS time: 8.8 months); and LC rates were 92.3%, 72.7%, and 72.7%, respectively. The eighth edition of tumor-node-metastasis (TNM) classification for esophageal cancer was the only significant OS-related factor (p = 0.0309). No grade ≥ 3 AEs were observed. Based on the low incidence of AEs and acceptable LC rate, PBT is a feasible option for the treatment of lung oligometastasis in esophageal cancer patients.

show abstract

“…79 Owing to its physical properties, PBT can deliver an ablative dose with minimal increase in risk of complications in many cases, PBT can provide opportunities for curation in oligometastatic HCC patients. 80 Further investigation to evaluate the efficacy of PBT would be worthwhile.…”

Section: Future Perspectivesmentioning

confidence: 99%

Current role of proton beam therapy in patients with hepatocellular carcinoma

Yoo

Park

2021

Int J Gastrointest Interv

View full text Add to dashboard Cite

Multi-Institutional Retrospective Analysis of the Outcomes of Proton Beam Therapy for Patients With 1 to 3 Pulmonary Oligometastases From Various Primary Cancers

Cited by 6 publications

References 22 publications

Comprehensive analysis of Japanese nationwide cohort data of particle beam therapy for pulmonary, liver and lymph node oligometastases: particle beam therapy versus high-precision X-ray radiotherapy

Comprehensive analysis of Japanese nationwide cohort data of particle beam therapy for pulmonary, liver and lymph node oligometastases: particle beam therapy versus high-precision X-ray radiotherapy

Proton Beam Therapy for Lung Oligometastatic Recurrence in Patients With Esophageal Cancer

Current role of proton beam therapy in patients with hepatocellular carcinoma

Contact Info

Product

Resources

About